⌘K

11:30:23·279d

PRRelease

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

SWTX· SpringWorks Therapeutics Inc.

Health Care

Original source

Companies

SWTX
SpringWorks Therapeutics Inc.
Health Care

Recent analyst ratings

Nov 20UpdateEvercore ISI$60.00
Feb 5UpdateGuggenheim$75.00
Dec 1UpdateBofA Securities$45.00
Sep 8UpdateJP Morgan$105.00
Aug 5UpdateHC Wainwright & Co.$137.00

Related

PR184d
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
PR248d
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
SEC286d
SEC Form 15-12G filed by SpringWorks Therapeutics Inc.
SEC290d
SEC Form SCHEDULE 13G filed by SpringWorks Therapeutics Inc.
INSIDER295d
Chief Operating Officer Edris Badreddin returned 169,712 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER295d
Director Lynch Daniel returned 93,004 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER295d
Director Lewis-Hall Freda C returned 24,727 shares to the company, closing all direct ownership in the company (SEC Form 4)
INSIDER295d
Director Hambleton Julie returned 14,155 shares to the company, closing all direct ownership in the company (SEC Form 4)